Literature DB >> 30303907

Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting.

Mark S DeFrancesco1, Richard N Waldman, Melissa M Pearlstone, Dana Karanik, Ryan Bernhisel, Jennifer Logan, Lindsey Alico, Royce T Adkins.   

Abstract

OBJECTIVE: To evaluate the feasibility and results of incorporating routine hereditary cancer risk assessment, counseling, and follow-up genetic testing in the community obstetrics and gynecology practice setting without referral to a genetic counselor.
METHODS: This prospective process intervention study was conducted with two obstetrics and gynecology practice groups (five sites). The intervention included baseline process assessment, refinement of clinic-specific patient screening workflows and tools, and training in hereditary cancer risk screening and follow-up. Outcomes related to hereditary cancer assessment and testing were measured during an 8-week postintervention period. Patients and health care providers were surveyed about satisfaction with the process. Data also were collected during the 8 weeks before the intervention to assess the effects of screening process improvements.
RESULTS: A total of 4,107 patients were seen during the postintervention period, and 92.8% (3,811) were assessed for hereditary cancer risk. Among those assessed, 906 of 3,811 (23.8%) women met National Comprehensive Cancer Network guidelines for genetic testing, and 813 of 906 (89.7%) eligible patients were offered genetic testing. A total of 165 of 4,107 (4.0%) women completed genetic testing and received a final test result. This represents a fourfold increase over genetic testing immediately before the intervention (1.1%) and an eightfold increase over the previous year (0.5%). Testing identified pathogenic variants in 9 of 165 (5.5%) tested women. All health care providers (15/15) reported that they will continue to use the established hereditary cancer risk assessment process. In addition, 98.8% (167/169) of patients who submitted a sample for genetic testing and completed a patient satisfaction survey stated that they were able to understand the information provided, and 97.6% (165/169) expressed satisfaction with the overall process.
CONCLUSION: It is feasible to incorporate hereditary cancer risk assessment, education, and testing into community obstetrics and gynecology practices. As a result, multigene panel testing identified significant cancer risks that otherwise would not have been recognized.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30303907     DOI: 10.1097/AOG.0000000000002916

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  Strategies to enhance identification of hereditary breast cancer gene carriers.

Authors:  Sonya Reid; Lucy B Spalluto; Tuya Pal
Journal:  Expert Rev Mol Diagn       Date:  2020-09-11       Impact factor: 5.225

2.  Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?

Authors:  Vida Henderson; Pam Ganschow; Catharine Wang; Kent F Hoskins
Journal:  Cancer       Date:  2021-08-23       Impact factor: 6.860

Review 3.  An overview of genetic services delivery for hereditary breast cancer.

Authors:  Sonya Reid; Lucy B Spalluto; Katie Lang; Anne Weidner; Tuya Pal
Journal:  Breast Cancer Res Treat       Date:  2022-01-26       Impact factor: 4.624

4.  Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.

Authors:  Kristin R Muessig; Jamilyn M Zepp; Erin Keast; Elizabeth E Shuster; Ana A Reyes; Briana Arnold; Chalinya Ingphakorn; Marian J Gilmore; Tia L Kauffman; Jessica Ezzell Hunter; Sarah Knerr; Heather S Feigelson; Katrina A B Goddard
Journal:  Hered Cancer Clin Pract       Date:  2022-02-10       Impact factor: 2.857

Review 5.  Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review.

Authors:  Michael P Douglas; Anika Kumar
Journal:  J Pers Med       Date:  2022-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.